Teladoc Health (NYSE:TDOC) Releases FY 2026 Earnings Guidance

by · The Markets Daily

Teladoc Health (NYSE:TDOC – Get Free Report) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of -1.000–0.750 for the period, compared to the consensus earnings per share estimate of -0.810. The company issued revenue guidance of $2.4 billion-$2.4 billion, compared to the consensus revenue estimate of $2.5 billion. Teladoc Health also updated its Q3 2026 guidance to -0.300–0.200 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on TDOC shares. Bank of America lifted their price target on shares of Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Canaccord Genuity Group increased their price target on Teladoc Health from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Citigroup lifted their price objective on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 5th. Five research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $7.57.

Get Our Latest Report on Teladoc Health

Teladoc Health Trading Down 1.6%

NYSE:TDOC traded down $0.15 on Wednesday, reaching $9.21. The company’s stock had a trading volume of 7,337,377 shares, compared to its average volume of 5,388,957. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89. The business’s 50-day moving average price is $8.16 and its two-hundred day moving average price is $6.54. The firm has a market cap of $1.66 billion, a PE ratio of -9.50 and a beta of 2.10. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80.

Teladoc Health (NYSE:TDOC – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Equities research analysts anticipate that Teladoc Health will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In related news, insider Adam C. Vandervoort sold 7,906 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $60,322.78. Following the sale, the insider directly owned 110,261 shares of the company’s stock, valued at approximately $841,291.43. The trade was a 6.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of Teladoc Health stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $47,275.48. Following the completion of the sale, the insider directly owned 57,671 shares in the company, valued at $440,029.73. This represents a 9.70% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock worth $299,058 over the last three months. 0.70% of the stock is currently owned by insiders.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

  • Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than analysts’ expected loss of $0.24. The earnings beat may support confidence in the company’s cost controls and near-term execution. Teladoc Health Reports Second Quarter 2026 Results
  • Positive Sentiment: A valuation analysis argued that TDOC remains undervalued after its severe five-year decline, with discounted-cash-flow and market-multiple estimates indicating potential upside. This could attract value-oriented investors, although it is not a formal company forecast. Teladoc Health Stock Still Looks Undervalued
  • Neutral Sentiment: Teladoc’s second-quarter results and accompanying materials provide investors with additional detail on operating metrics and management’s outlook. The earnings release itself did not eliminate concerns about the company’s longer-term path to profitability. Teladoc Health Earnings Slide Deck
  • Negative Sentiment: Third-quarter guidance was below Wall Street expectations. Teladoc forecast an adjusted loss of $0.20–$0.30 per share versus a consensus loss of $0.17, while revenue guidance of $569 million–$609 million trailed the $629.1 million consensus estimate.
  • Negative Sentiment: Full-year 2026 revenue guidance of approximately $2.4 billion was below the $2.5 billion analyst estimate. The company also remains unprofitable, reporting a negative 6.81% net margin and negative 11.45% return on equity.
  • Negative Sentiment: A law firm issued a shareholder-investigation solicitation concerning possible fiduciary-duty issues involving Teladoc insiders. While unproven and promotional in nature, such announcements can add headline and litigation risk.

Institutional Investors Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc boosted its stake in shares of Teladoc Health by 412.1% during the 3rd quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after buying an additional 3,210 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock valued at $31,000 after buying an additional 2,810 shares during the last quarter. Van ECK Associates Corp increased its holdings in Teladoc Health by 101.4% during the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after buying an additional 4,607 shares during the last quarter. Johnson Financial Group Inc. raised its position in Teladoc Health by 41,045.8% during the third quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock worth $76,000 after acquiring an additional 9,851 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new stake in Teladoc Health in the fourth quarter valued at $82,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

Featured Stories